Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GU-187: Alternative Cabozantinib Dosing Schedule in mRCC and NETs
NCT05263050Phase 2Recruiting
- Sponsor
- Fox Chase Cancer Center
- Start
- Jan 2022
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cabozantinib in renal cell carcinoma (RCC), Neuroendocrine Neoplasm (NEN), sponsored by Fox Chase Cancer Center. Started Jan 2022; status: recruiting.
02
Drugs
cabozantinib
03
Conditions
renal cell carcinoma (RCC)Neuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT05263050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05263050.